Andrew M. Evens, DO, MSc, FACP

Andrew M. Evens, DO, MSc, director of the Lymphoma Program and associate director for Clinical Services at the Rutgers Cancer Institute of New Jersey, discusses the significance of the results from the phase III ECHELON-1 trial in which patients with stage III/IV classical Hodgkin lymphoma (cHL) were treated with the combination of brentuximab vedotin (Adcetris) plus doxorubicin, vinblastine, and dacarbazine (A+AVD).

The primary endpoint was progression-free survival (PFS). The trial results demonstrated an absolute improvement of 5% in PFS by independent review panel and 6.6% by investigator. The addition may be small, Evens notes, but it means that 20 patients need to be treated with the addition of brentuximab vedotin to prevent a modified PFS in 1 patient.

Videos

Andrew M. Evens, DO, MSc, discusses the significance of the results from the phase III ECHELON-1 trial in which patients with stage III/IV classical Hodgkin lymphoma were treated with the combination of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine.

Andrew M. Evens, DO, MSc, FACP | Authors

Articles

Brentuximab Vedotin Adds Benefit to A+AVD Therapy in cHL